IFNG and metabolic dysfunction-associated steatohepatitis: When compared to the vehicle, IFN-γ expression was significantly reduced after I-BET151 treatment in the NASH study as well as in the 5 and 15 mg/kg I-BET151-treatment groups in the fibrosis study (p < 0.05, one way ANOVA followed by Fisher LSD test).